Abstract
Glioblastoma is the most common, aggressive and lethal brain tumor in adults. However, current therapeutic protocols have low success rates and average overall survival is less than 15 months. The resistance to therapy is largely a result of the remarkable cellular and phenotypical heterogeneity that characterizes this type of tumor. The discovery of a subpopulation of cells exhibiting stem cell properties within the tumor bulk has profound implications for therapy as increasing evidence indicates that these cells, glioblastoma stem cells (GSCs), are responsible for the origin, maintenance and recurrence of the glioblastomas. These findings highlight the need to characterize GSCs in order to find novel treatments directly targeted specifically against them. In this review, we summarize the current knowledge regarding this issue, including some recent and relevant patents.
Keywords: Glioblastoma, glioblastoma stem cells, molecular target, therapy.
Recent Patents on Anti-Cancer Drug Discovery
Title:Therapeutic Strategies Targeting Glioblastoma Stem Cells
Volume: 8 Issue: 3
Author(s): Estefania Carrasco-Garcia, Nicolas Sampron, Paula Aldaz, Olatz Arrizabalaga, Jorge Villanua, Cristina Barrena, Irune Ruiz, Mariano Arrazola, Charles Lawrie and Ander Matheu
Affiliation:
Keywords: Glioblastoma, glioblastoma stem cells, molecular target, therapy.
Abstract: Glioblastoma is the most common, aggressive and lethal brain tumor in adults. However, current therapeutic protocols have low success rates and average overall survival is less than 15 months. The resistance to therapy is largely a result of the remarkable cellular and phenotypical heterogeneity that characterizes this type of tumor. The discovery of a subpopulation of cells exhibiting stem cell properties within the tumor bulk has profound implications for therapy as increasing evidence indicates that these cells, glioblastoma stem cells (GSCs), are responsible for the origin, maintenance and recurrence of the glioblastomas. These findings highlight the need to characterize GSCs in order to find novel treatments directly targeted specifically against them. In this review, we summarize the current knowledge regarding this issue, including some recent and relevant patents.
Export Options
About this article
Cite this article as:
Carrasco-Garcia Estefania, Sampron Nicolas, Aldaz Paula, Arrizabalaga Olatz, Villanua Jorge, Barrena Cristina, Ruiz Irune, Arrazola Mariano, Lawrie Charles and Matheu Ander, Therapeutic Strategies Targeting Glioblastoma Stem Cells, Recent Patents on Anti-Cancer Drug Discovery 2013; 8 (3) . https://dx.doi.org/10.2174/15748928113089990002
DOI https://dx.doi.org/10.2174/15748928113089990002 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heterocyclic Analogues as Kinase Inhibitors: A Focus Review
Current Topics in Medicinal Chemistry Challenges in the Management of Paediatric Febrile Neutropenia
Current Pediatric Reviews Therapeutic Outlook of Pyrazole Analogs: A Mini Review
Mini-Reviews in Medicinal Chemistry Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets The AmpliChip: A Review of its Analytic and Clinical Validity and Clinical Utility
Current Drug Safety Association of GRP78, HIF-1α and BAG3 Expression with the Severity of Chronic Lymphocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry Antibacterial and Antitumorigenic Properties of Microcin E492, a Pore- Forming Bacteriocin
Current Pharmaceutical Biotechnology NAD in Skin: Therapeutic Approaches for Niacin
Current Pharmaceutical Design Systems Biology Approaches to Pancreatic Cancer Detection, Prevention and Treatment
Current Pharmaceutical Design Sunflower Trypsin Inhibitor 1 as a Molecular Scaffold for Drug Discovery
Current Pharmaceutical Design Current Advances in Antibody Immobilization on Different Surfaces and Beads
Current Proteomics Immunology of Gynecologic Neoplasms: Analysis of the Prognostic Significance of the Immune Status
Current Cancer Drug Targets Farnesyltransferase Inhibitors: A Detailed Chemical View on an Elusive Biological Problem
Current Medicinal Chemistry Proline-Rich Peptides: Multifunctional Bioactive Molecules as New Potential Therapeutic Drugs
Current Protein & Peptide Science Targeted Nanostructured Lipid Carriers for Delivery of Paclitaxel to Cancer Cells: Preparation, Characterization, and Cell Toxicity
Current Drug Delivery The Impact of HAART on HPV-Related Cervical Disease
Current HIV Research Process Variables and Design of Experiments in Liposome and Nanoliposome Research
Mini-Reviews in Medicinal Chemistry In Vitro and In Vivo Evaluation of DMSO and Azone as Penetration Enhancers for Cutaneous Application of Celecoxib
Current Drug Delivery Editorial [Hot Topic: Akt Pathway in Oncogenesis and as a Target for Anti-Cancer Therapy (Guest Editor: Jin Q. Cheng) ]
Current Cancer Drug Targets Prostate Cancer Gene Expression Marker 1 (PCGEM1): A Patented Prostate- Specific Non-Coding Gene and Regulator of Prostate Cancer Progression
Recent Patents on DNA & Gene Sequences